NCT07333573尚未招募1 期
A Single-arm, Open-label Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Hypoxia-Inducible CD73/AXL-Targeting CAR-T Cells (XW-LTH-03) in Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2026年1月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
This is a single-arm, open-label clinical study evaluating the safety and preliminary efficacy of a novel hypoxia-inducible, bispecific CD73/AXL-targeting CAR-T cell product, XW-LTH-03, in patients with stage IV gastric cancer (GC). The primary objective is to assess the safety and tolerability of XW-LTH-03 infusions. Secondary objectives include the evaluation of its antitumor efficacy and the characterization of its pharmacokinetic profile by measuring the in vivo expansion and persistence of the CAR-T cells. Exploratory analyses aim to identify potential biomarkers associated with clinical response and toxicity, as well as to investigate the cellular and molecular mechanisms underlying potential treatment resistance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years, male or female.
- •Clinically judged as unresectable Stage IV gastric cancer that has progressed on or is intolerant to standard therapy, or patients who voluntarily forego standard therapy.
- •Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.
- •ECOG Performance Status score of ≤
- •Life expectancy of ≥ 3 months.
- •At least one measurable lesion (≥ 1 cm).
- •More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤
- •Adequate organ function and bone marrow reserve, as defined by the following laboratory values within a specified period before enrollment:
- •1. Hemoglobin (Hb) ≥ 90 g/L.
- •Absolute Neutrophil Count (ANC) ≥ 1.0 × 10^9/L.
- •Absolute Lymphocyte Count ≥ 0.5 × 10^9/L.
- •Platelet count ≥ 100 × 10^9/L.
- •Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN).
- •6. Serum amylase and lipase ≤ 1.0 × ULN.
- •Total bilirubin ≤ 1.5 × ULN.
- •Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
- •9. Prothrombin Time (PT) or International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) < 1.5 × ULN. (Patients receiving warfarin or heparin anticoagulation therapy may be enrolled if no underlying abnormality in these parameters is suspected, but require close monitoring with at least weekly testing until INR is stable).
- •9. Adequate cardiac and pulmonary function.
- •Women of childbearing potential must have a negative pregnancy test within 7 days before treatment initiation. All subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.
- •11. Voluntary signing of a written informed consent form, good compliance, and willingness to cooperate with follow-up.
排除标准
- •Active, known, or highly suspected autoimmune disease.
- •Patients with brain metastases who have active central nervous system symptoms. (Note: Patients with brain metastases who completed radiotherapy at least 3 months prior to enrollment and remain asymptomatic from CNS disease may be eligible).
- •Active, uncontrolled systemic infection.
- •Receiving high-dose corticosteroids (>10 mg/day of methylprednisolone or equivalent doses of other corticosteroids) or other immunosuppressive therapy within 14 days prior to enrollment.
- •History of severe allergy to other monoclonal antibodies.
- •Intolerance or allergy to the investigational drug.
- •History of interstitial lung disease.
- •Evidence of organ failure:
- •Cardiac: Class III or IV heart failure (per NYHA or other applicable criteria).
- •Hepatic: Class C liver function as per Child-Pugh score.
- •Renal: Renal failure or uremia stage.
- •Pulmonary: Symptoms of severe respiratory failure.
- •Neurological: Impaired consciousness.
- •Active Hepatitis B (HBsAg positive with detectable HBV DNA), active Hepatitis C (HCV RNA positive), or HIV antibody positive.
- •History of organ transplantation.
- •Active gastrointestinal bleeding, or history of gastrointestinal bleeding within the past month.
- •History of drug abuse, or psychological/psychiatric disorders that may compromise compliance with the study.
- •Any unstable condition or situation that may jeopardize the patient's safety or compliance in the study.
- •Thyroid dysfunction.
- •Prior treatment with any form of adoptive T-cell therapy.
- •Currently receiving anticoagulant or antiplatelet therapy.
- •Major surgery or significant trauma within 4 weeks prior to enrollment.
- •History of other malignant tumors within the past 3 years.
- •Judged by the investigator as unsuitable for cell therapy.
研究组 & 干预措施
XW-LTH-03 Infusion
Experimental
干预措施: XW-LTH-03 Infusion (Biological)
结局指标
主要结局
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: 3 months
Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
时间窗: 3 months
Incidence of Dose-Limiting Toxicities (DLTs)
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
尚未招募
4 期
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic CancerNCT07302841Tianjin Medical University Cancer Institute and Hospital28
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
招募中
2 期
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNCT07266493Shanghai Zhongshan Hospital26
招募中
1 期
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF MutationsNCT07288580Shanghai Euhearing Therapeutics Co., Ltd30